Journal of Refractive Surgery

The articles prior to January 2011 are part of the back file collection and are not available with a current paid subscription. To access the article, you may purchase it or purchase the complete back file collection here

Original Article 

LASIK for Myopia Using the Zeiss VisuMax Femtosecond Laser and MEL 80 Excimer Laser

Kathleen Kunert, MD; Marcus Blum, MD; Annika Gille; Walter Sekundo, MD

Abstract

PURPOSE

To assess the efficacy, safety, and predictability of the VisuMax femtosecond laser (Carl Zeiss Meditec).

METHODS

In a prospective, multicenter clinical trial, 32 eyes of 17 patients underwent LASIK and flap creation with the VisuMax femtosecond laser and ablation with the MEL 80 excimer laser (Carl Zeiss Meditec). Mean patient age was 35 years (range: 23 to 52 years). Mean preoperative spherical equivalent refraction was -4.04±1.39 diopters (D) (range: -1.50 to -7.25 D), and the planned flap thickness was 110, 120, 140, and 150 µm.

RESULTS

At the 3-month postoperative examination, all eyes had best spectacle-corrected visual acuity of 20/25 and uncorrected visual acuity (UCVA) of 20/40; 91% of eyes reached UCVA of 20/20 or better. Ninety-four percent of eyes were within ±0.50 D of the planned correction. Complications were limited to one case of suction loss, and no other adverse events were noted at 3 months. The flaps were planar and the mean achieved central flap thickness was 118±9.2 µm for an attempted thickness of 120 µm.

CONCLUSIONS

The investigators achieved LASIK outcomes exceeding the US Food and Drug Administration guidelines for refractive procedures in this series of myopic eyes using the VisuMax femtosecond laser and MEL 80 excimer laser. The curved contact lens of the applanation glass combined with low suction permitted continuous fixation during treatment. [J Refract Surg. 2009;25:350-356.]

AUTHORS

From the Department of Ophthalmology, Helios Hospital, Erfurt (Blum, Kunert); Carl Zeiss Meditec, Jena (Gille); and University Eye Hospital, Mainz (Sekundo), Germany.

Ms Gille is a paid employee of Carl Zeiss Meditec, Jena, Germany. The remaining authors have no financial or proprietary interest in the materials presented herein.

The authors thank John Dishler, MD, Denver, Colo, for his helpful comments.

Correspondence: Marcus Blum, MD, Augenklinik des Helios Klinikum Erfurt, Nordhäusser Str 74, 99089 Erfurt, Germany. Tel: 49 0361 7812070; Fax: 49 0361 7812072; E-mail: mblum@erfurt.helios-kliniken.de

Received: May 31, 2007; Accepted: June 10, 2008

Posted online: August 15, 2008

Abstract

PURPOSE

To assess the efficacy, safety, and predictability of the VisuMax femtosecond laser (Carl Zeiss Meditec).

METHODS

In a prospective, multicenter clinical trial, 32 eyes of 17 patients underwent LASIK and flap creation with the VisuMax femtosecond laser and ablation with the MEL 80 excimer laser (Carl Zeiss Meditec). Mean patient age was 35 years (range: 23 to 52 years). Mean preoperative spherical equivalent refraction was -4.04±1.39 diopters (D) (range: -1.50 to -7.25 D), and the planned flap thickness was 110, 120, 140, and 150 µm.

RESULTS

At the 3-month postoperative examination, all eyes had best spectacle-corrected visual acuity of 20/25 and uncorrected visual acuity (UCVA) of 20/40; 91% of eyes reached UCVA of 20/20 or better. Ninety-four percent of eyes were within ±0.50 D of the planned correction. Complications were limited to one case of suction loss, and no other adverse events were noted at 3 months. The flaps were planar and the mean achieved central flap thickness was 118±9.2 µm for an attempted thickness of 120 µm.

CONCLUSIONS

The investigators achieved LASIK outcomes exceeding the US Food and Drug Administration guidelines for refractive procedures in this series of myopic eyes using the VisuMax femtosecond laser and MEL 80 excimer laser. The curved contact lens of the applanation glass combined with low suction permitted continuous fixation during treatment. [J Refract Surg. 2009;25:350-356.]

AUTHORS

From the Department of Ophthalmology, Helios Hospital, Erfurt (Blum, Kunert); Carl Zeiss Meditec, Jena (Gille); and University Eye Hospital, Mainz (Sekundo), Germany.

Ms Gille is a paid employee of Carl Zeiss Meditec, Jena, Germany. The remaining authors have no financial or proprietary interest in the materials presented herein.

The authors thank John Dishler, MD, Denver, Colo, for his helpful comments.

Correspondence: Marcus Blum, MD, Augenklinik des Helios Klinikum Erfurt, Nordhäusser Str 74, 99089 Erfurt, Germany. Tel: 49 0361 7812070; Fax: 49 0361 7812072; E-mail: mblum@erfurt.helios-kliniken.de

Received: May 31, 2007; Accepted: June 10, 2008

Posted online: August 15, 2008

10.3928/1081597X-20090401-01

Advertisement

Sign up to receive

Journal E-contents
Advertisement